Dimethyl sulfoxide-induced toxicity in cord blood stem cell transplantation: report of three cases and review of the literature.
Umbilical cord blood transplantation using nonmyeloablative conditioning is currently considered by many as a valid potential alternative for any patient who requires an unrelated donor allograft and who is without a suitably matched and readily available volunteer. Dimethyl sulfoxide (DMSO) has been used for years as a cryoprotectant agent; it acts by penetrating the cell and binding water molecules and it has been described as harmless for the individual who receives it in limited amounts. In this paper, we describe 3 cases of DMSO-induced toxicities and briefly review the most common adverse reactions of the DMSO when used as a cryopreservation agent for the long-term storage of cord blood cells. Two of the 3 cases had a dismal prognosis. A brief review of the literature is presented.
Ruiz-Delgado
Guillermo J
GJ
Centro de Hematología y Medicina Interna de Puebla, Laboratorios Clinicos de Puebla, Puebla, México. gruiz2@clinicaruiz.com
Mancías-Guerra
Consuelo
C
Tamez-Gómez
Edna L
EL
Rodríguez-Romo
Laura N
LN
López-Otero
Avril
A
Hernández-Arizpe
Ana
A
Gómez-Almaguer
David
D
Ruiz-Argüelles
Guillermo J
GJ
D018952:Antigens, CD34; D002648:Child; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D003451:Cryoprotective Agents / Q000009:adverse effects*; D004121:Dimethyl Sulfoxide / Q000009:adverse effects*; D005199:Fanconi Anemia / Q000628:therapy; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008297:Male
D018952:Antigens, CD34; D003451:Cryoprotective Agents; D004121:Dimethyl Sulfoxide